



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

TECHNICAL CENTER 1600/2900

JUN 19 2002

RECEIVED

Applicant(s): Chen et al.

Serial No.: 10/046,526 ✓

Group Art Unit No.: 1614

Filed: January 10, 2002 ✓

Examiner: n/a

For: Substituted Arylamine Derivatives and Methods of Use

Docket No.: A-735A

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

Applicant's(s') position regarding this information and its relevancy remains unchanged.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

June 10, 2002
Date

Centrell B. Brown
Signature

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

A handwritten signature in black ink that reads "Joseph W. Bullock". The signature is written in a cursive style with a large, looped "J" and a distinct "B".

Joseph W. Bullock

Attorney/Agent for Applicant(s)

Registration No.: 37,103

Phone: (805) 447-7966

Date: June 10, 2002

Please send all future correspondence to:

US Patent Operations/ JWB cpb
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799